TW201410706A - 抗－ｐｃｓｋ９抗體、調配物、劑量及使用方法 - Google Patents

Info

Publication number

TW201410706A

TW201410706A TW102121268A TW102121268A TW201410706A TW 201410706 A TW201410706 A TW 201410706A TW 102121268 A TW102121268 A TW 102121268A TW 102121268 A TW102121268 A TW 102121268A TW 201410706 A TW201410706 A TW 201410706A

Authority

TW

Taiwan

Prior art keywords

seq

antibody

hvr

pcsk9

amino acid

Prior art date

2012-06-15

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 243
• 239000000203 mixture Substances 0.000 title claims abstract description 176
• 238000009472 formulation Methods 0.000 title abstract description 59
• 108010028554 LDL Cholesterol Proteins 0.000 claims description 181
• 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 173
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 144
• 241000282414 Homo sapiens Species 0.000 claims description 107
• 239000003814 drug Substances 0.000 claims description 105
• 230000002829 reductive effect Effects 0.000 claims description 93
• 210000004027 cell Anatomy 0.000 claims description 90
• 230000027455 binding Effects 0.000 claims description 84
• 150000001413 amino acids Chemical group 0.000 claims description 83
• 229940079593 drug Drugs 0.000 claims description 73
• 238000008214 LDL Cholesterol Methods 0.000 claims description 68
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 65
• 239000012634 fragment Substances 0.000 claims description 64
• 235000012000 cholesterol Nutrition 0.000 claims description 60
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 59
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 59
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 58
• 150000007523 nucleic acids Chemical class 0.000 claims description 57
• 238000011282 treatment Methods 0.000 claims description 52
• 108020004707 nucleic acids Proteins 0.000 claims description 48
• 102000039446 nucleic acids Human genes 0.000 claims description 48
• 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 46
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
• 238000007920 subcutaneous administration Methods 0.000 claims description 35
• 229940071643 prefilled syringe Drugs 0.000 claims description 30
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 26
• 229910052717 sulfur Inorganic materials 0.000 claims description 25
• 239000013598 vector Substances 0.000 claims description 25
• 229910052739 hydrogen Inorganic materials 0.000 claims description 24
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 23
• 208000035150 Hypercholesterolemia Diseases 0.000 claims description 23
• 238000004519 manufacturing process Methods 0.000 claims description 21
• 229920000136 polysorbate Polymers 0.000 claims description 19
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 18
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 18
• 239000002253 acid Substances 0.000 claims description 18
• 229960005370 atorvastatin Drugs 0.000 claims description 18
• OZBJWQQAAQSQPL-WCCKRBBISA-N acetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N OZBJWQQAAQSQPL-WCCKRBBISA-N 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 12
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 10
• 230000002401 inhibitory effect Effects 0.000 claims description 10
• 229960002855 simvastatin Drugs 0.000 claims description 10
• 108010007622 LDL Lipoproteins Proteins 0.000 claims description 9
• 229910052731 fluorine Inorganic materials 0.000 claims description 9
• 229910052698 phosphorus Inorganic materials 0.000 claims description 9
• 229950008882 polysorbate Drugs 0.000 claims description 9
• 229960000672 rosuvastatin Drugs 0.000 claims description 9
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 9
• 150000001412 amines Chemical class 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 8
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 6
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 6
• 229960004844 lovastatin Drugs 0.000 claims description 5
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 5
• 108010023302 HDL Cholesterol Proteins 0.000 claims description 4
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 4
• AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 4
• 125000003277 amino group Chemical group 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 4
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
• 229960003765 fluvastatin Drugs 0.000 claims description 4
• AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 4
• 229950009116 mevastatin Drugs 0.000 claims description 4
• BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 4
• 229960002965 pravastatin Drugs 0.000 claims description 4
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 4
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 3
• 229960002797 pitavastatin Drugs 0.000 claims description 3
• 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
• 150000002148 esters Chemical class 0.000 claims description 2
• 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims 5
• FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
• 125000003275 alpha amino acid group Chemical group 0.000 description 218
• 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 169
• 239000000427 antigen Substances 0.000 description 59
• 102000036639 antigens Human genes 0.000 description 56
• 108091007433 antigens Proteins 0.000 description 56
• 208000029078 coronary artery disease Diseases 0.000 description 50
• 108090000623 proteins and genes Proteins 0.000 description 48
• 230000008859 change Effects 0.000 description 46
• 102000053786 human PCSK9 Human genes 0.000 description 42
• 102000004169 proteins and genes Human genes 0.000 description 42
• 102000000853 LDL receptors Human genes 0.000 description 41
• 108010001831 LDL receptors Proteins 0.000 description 41
• 235000018102 proteins Nutrition 0.000 description 40
• 229920001213 Polysorbate 20 Polymers 0.000 description 38
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 38
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 38
• 238000006467 substitution reaction Methods 0.000 description 37
• 229940068977 polysorbate 20 Drugs 0.000 description 36
• 239000000902 placebo Substances 0.000 description 34
• 229940068196 placebo Drugs 0.000 description 34
• 230000000694 effects Effects 0.000 description 33
• 238000004458 analytical method Methods 0.000 description 30
• 235000001014 amino acid Nutrition 0.000 description 26
• 125000000539 amino acid group Chemical group 0.000 description 25
• 230000009467 reduction Effects 0.000 description 25
• 210000002966 serum Anatomy 0.000 description 25
• 241000699670 Mus sp. Species 0.000 description 24
• 239000000872 buffer Substances 0.000 description 24
• 201000010099 disease Diseases 0.000 description 24
• 235000014304 histidine Nutrition 0.000 description 24
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 24
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 22
• 230000001965 increasing effect Effects 0.000 description 22
• 238000012216 screening Methods 0.000 description 22
• 238000002560 therapeutic procedure Methods 0.000 description 21
• 229940124597 therapeutic agent Drugs 0.000 description 20
• BHKSYEZGBQDNRW-SCGRZTRASA-N C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O Chemical compound C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O BHKSYEZGBQDNRW-SCGRZTRASA-N 0.000 description 19
• 229940024606 amino acid Drugs 0.000 description 19
• 230000004071 biological effect Effects 0.000 description 19
• 230000003647 oxidation Effects 0.000 description 19
• 238000007254 oxidation reaction Methods 0.000 description 19
• 108090000765 processed proteins & peptides Proteins 0.000 description 19
• 238000001542 size-exclusion chromatography Methods 0.000 description 18
• -1 see Hudson et al Proteins 0.000 description 17
• 239000000243 solution Substances 0.000 description 17
• 239000002953 phosphate buffered saline Substances 0.000 description 16
• 108060003951 Immunoglobulin Proteins 0.000 description 15
• 239000001747 Potassium fumarate Substances 0.000 description 15
• 238000003556 assay Methods 0.000 description 15
• 102000018358 immunoglobulin Human genes 0.000 description 15
• 238000003780 insertion Methods 0.000 description 14
• 230000037431 insertion Effects 0.000 description 14
• 239000000523 sample Substances 0.000 description 14
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 13
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 13
• 241000699666 Mus <mouse, genus> Species 0.000 description 13
• 238000012217 deletion Methods 0.000 description 13
• 230000037430 deletion Effects 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 238000004255 ion exchange chromatography Methods 0.000 description 13
• 230000004481 post-translational protein modification Effects 0.000 description 13
• 102000004196 processed proteins & peptides Human genes 0.000 description 13
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
• 102000025171 antigen binding proteins Human genes 0.000 description 12
• 108091000831 antigen binding proteins Proteins 0.000 description 12
• 206010012601 diabetes mellitus Diseases 0.000 description 12
• 210000004185 liver Anatomy 0.000 description 12
• 108010010234 HDL Lipoproteins Proteins 0.000 description 11
• 206010028980 Neoplasm Diseases 0.000 description 11
• 230000001976 improved effect Effects 0.000 description 11
• 230000000250 revascularization Effects 0.000 description 11
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
• 201000001320 Atherosclerosis Diseases 0.000 description 10
• 208000024172 Cardiovascular disease Diseases 0.000 description 10
• 208000032928 Dyslipidaemia Diseases 0.000 description 10
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 10
• 208000017170 Lipid metabolism disease Diseases 0.000 description 10
• 101710105047 Lipoprotein B Proteins 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 230000003143 atherosclerotic effect Effects 0.000 description 10
• 208000035475 disorder Diseases 0.000 description 10
• 238000010494 dissociation reaction Methods 0.000 description 10
• 230000005593 dissociations Effects 0.000 description 10
• 229940127121 immunoconjugate Drugs 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 239000012071 phase Substances 0.000 description 10
• 229920001184 polypeptide Polymers 0.000 description 10
• 229930006000 Sucrose Natural products 0.000 description 9
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 9
• 238000002586 coronary angiography Methods 0.000 description 9
• 230000003828 downregulation Effects 0.000 description 9
• 230000004927 fusion Effects 0.000 description 9
• 230000014509 gene expression Effects 0.000 description 9
• 229960001031 glucose Drugs 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 238000005259 measurement Methods 0.000 description 9
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
• 239000005720 sucrose Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
• 102000007330 LDL Lipoproteins Human genes 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 230000002411 adverse Effects 0.000 description 8
• 230000001588 bifunctional effect Effects 0.000 description 8
• 229940127089 cytotoxic agent Drugs 0.000 description 8
• 238000001514 detection method Methods 0.000 description 8
• 238000005516 engineering process Methods 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 230000013595 glycosylation Effects 0.000 description 8
• 238000006206 glycosylation reaction Methods 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 150000002632 lipids Chemical class 0.000 description 8
• 238000003752 polymerase chain reaction Methods 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 7
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 7
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 7
• 230000002776 aggregation Effects 0.000 description 7
• 238000004220 aggregation Methods 0.000 description 7
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 229940098773 bovine serum albumin Drugs 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 239000013078 crystal Substances 0.000 description 7
• 235000018417 cysteine Nutrition 0.000 description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
• 239000002254 cytotoxic agent Substances 0.000 description 7
• 239000008103 glucose Substances 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 208000010125 myocardial infarction Diseases 0.000 description 7
• 150000002482 oligosaccharides Chemical class 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 230000002285 radioactive effect Effects 0.000 description 7
• 238000003127 radioimmunoassay Methods 0.000 description 7
• 230000036262 stenosis Effects 0.000 description 7
• 108700012359 toxins Proteins 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 6
• 241000196324 Embryophyta Species 0.000 description 6
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 6
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 6
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 6
• 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 239000002246 antineoplastic agent Substances 0.000 description 6
• 229960003589 arginine hydrochloride Drugs 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 231100000599 cytotoxic agent Toxicity 0.000 description 6
• 230000029087 digestion Effects 0.000 description 6
• 238000001647 drug administration Methods 0.000 description 6
• 230000036541 health Effects 0.000 description 6
• PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 6
• 229960000645 histamine hydrochloride Drugs 0.000 description 6
• 238000003384 imaging method Methods 0.000 description 6
• 238000001802 infusion Methods 0.000 description 6
• 208000017169 kidney disease Diseases 0.000 description 6
• 238000002372 labelling Methods 0.000 description 6
• 230000003902 lesion Effects 0.000 description 6
• 229920001542 oligosaccharide Polymers 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 238000012552 review Methods 0.000 description 6
• 239000007790 solid phase Substances 0.000 description 6
• 238000003860 storage Methods 0.000 description 6
• 239000003053 toxin Substances 0.000 description 6
• 231100000765 toxin Toxicity 0.000 description 6
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
• 108010087819 Fc receptors Proteins 0.000 description 5
• 102000009109 Fc receptors Human genes 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 206010020772 Hypertension Diseases 0.000 description 5
• 241000282567 Macaca fascicularis Species 0.000 description 5
• 208000031481 Pathologic Constriction Diseases 0.000 description 5
• 230000009824 affinity maturation Effects 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 239000012472 biological sample Substances 0.000 description 5
• 229960002685 biotin Drugs 0.000 description 5
• 235000020958 biotin Nutrition 0.000 description 5
• 239000011616 biotin Substances 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 230000001900 immune effect Effects 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 238000010253 intravenous injection Methods 0.000 description 5
• 210000003292 kidney cell Anatomy 0.000 description 5
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 208000037804 stenosis Diseases 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 241000282693 Cercopithecidae Species 0.000 description 4
• 238000008723 Direct LDL Methods 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 208000006011 Stroke Diseases 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 150000001720 carbohydrates Chemical group 0.000 description 4
• 230000000747 cardiac effect Effects 0.000 description 4
• 230000007211 cardiovascular event Effects 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
• 208000020832 chronic kidney disease Diseases 0.000 description 4
• 238000012875 competitive assay Methods 0.000 description 4
• 230000009137 competitive binding Effects 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 239000000562 conjugate Substances 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 208000019622 heart disease Diseases 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 4
• 239000003094 microcapsule Substances 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• 230000003285 pharmacodynamic effect Effects 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 230000005180 public health Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 235000020183 skimmed milk Nutrition 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 108090001008 Avidin Proteins 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 208000014882 Carotid artery disease Diseases 0.000 description 3
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
• 241000699802 Cricetulus griseus Species 0.000 description 3
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 208000032382 Ischaemic stroke Diseases 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• 208000001145 Metabolic Syndrome Diseases 0.000 description 3
• 206010027525 Microalbuminuria Diseases 0.000 description 3
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
• OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 3
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 206010036790 Productive cough Diseases 0.000 description 3
• 208000017442 Retinal disease Diseases 0.000 description 3
• 206010038923 Retinopathy Diseases 0.000 description 3
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
• 208000002223 abdominal aortic aneurysm Diseases 0.000 description 3
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
• 239000008351 acetate buffer Substances 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 238000012867 alanine scanning Methods 0.000 description 3
• 229940049595 antibody-drug conjugate Drugs 0.000 description 3
• 239000002220 antihypertensive agent Substances 0.000 description 3
• 229940127088 antihypertensive drug Drugs 0.000 description 3
• 208000007474 aortic aneurysm Diseases 0.000 description 3
• 229960003121 arginine Drugs 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 235000009697 arginine Nutrition 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 238000013357 binding ELISA Methods 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 238000002591 computed tomography Methods 0.000 description 3
• 238000004590 computer program Methods 0.000 description 3
• 229920001577 copolymer Polymers 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 238000002784 cytotoxicity assay Methods 0.000 description 3
• 231100000263 cytotoxicity test Toxicity 0.000 description 3
• 239000000032 diagnostic agent Substances 0.000 description 3
• 229940039227 diagnostic agent Drugs 0.000 description 3
• 230000035487 diastolic blood pressure Effects 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 239000013628 high molecular weight specie Substances 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 210000003141 lower extremity Anatomy 0.000 description 3
• 238000002595 magnetic resonance imaging Methods 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 201000001119 neuropathy Diseases 0.000 description 3
• 230000007823 neuropathy Effects 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 238000013146 percutaneous coronary intervention Methods 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 3
• 230000000306 recurrent effect Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000013207 serial dilution Methods 0.000 description 3
• 230000000391 smoking effect Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 210000003802 sputum Anatomy 0.000 description 3
• 208000024794 sputum Diseases 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 230000035488 systolic blood pressure Effects 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 230000000472 traumatic effect Effects 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 210000000707 wrist Anatomy 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 2
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 206010060965 Arterial stenosis Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010003658 Atrial Fibrillation Diseases 0.000 description 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
• 102100033620 Calponin-1 Human genes 0.000 description 2
• 206010008479 Chest Pain Diseases 0.000 description 2
• 206010008635 Cholestasis Diseases 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
• 208000005189 Embolism Diseases 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 2
• 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 108010073807 IgG Receptors Proteins 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 102000004895 Lipoproteins Human genes 0.000 description 2
• 108090001030 Lipoproteins Proteins 0.000 description 2
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 108090000854 Oxidoreductases Proteins 0.000 description 2
• 102000004316 Oxidoreductases Human genes 0.000 description 2
• 102000003992 Peroxidases Human genes 0.000 description 2
• 239000004372 Polyvinyl alcohol Substances 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 description 2
• WNWXXAPGHTVCDL-OKDJMAGBSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 WNWXXAPGHTVCDL-OKDJMAGBSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 229940034653 advicor Drugs 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
• 230000001668 ameliorated effect Effects 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000000611 antibody drug conjugate Substances 0.000 description 2
• 239000003529 anticholesteremic agent Substances 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
• 108010044540 auristatin Proteins 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 239000008228 bacteriostatic water for injection Substances 0.000 description 2
• 229960003872 benzethonium Drugs 0.000 description 2
• 238000005251 capillar electrophoresis Methods 0.000 description 2
• 229940077731 carbohydrate nutrients Drugs 0.000 description 2
• 238000007675 cardiac surgery Methods 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 229940044683 chemotherapy drug Drugs 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 238000009295 crossflow filtration Methods 0.000 description 2
• 238000005138 cryopreservation Methods 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000001212 derivatisation Methods 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 235000021045 dietary change Nutrition 0.000 description 2
• SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 2
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 239000013583 drug formulation Substances 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 108010028531 enomycin Proteins 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 231100000776 exotoxin Toxicity 0.000 description 2
• 239000002095 exotoxin Substances 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 230000008014 freezing Effects 0.000 description 2
• 230000033581 fucosylation Effects 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 238000003209 gene knockout Methods 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000003966 growth inhibitor Substances 0.000 description 2
• 229920001519 homopolymer Polymers 0.000 description 2
• 208000003532 hypothyroidism Diseases 0.000 description 2
• 230000002989 hypothyroidism Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 238000001155 isoelectric focusing Methods 0.000 description 2
• 238000009533 lab test Methods 0.000 description 2
• 238000012417 linear regression Methods 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000012669 liquid formulation Substances 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 238000013227 male C57BL/6J mice Methods 0.000 description 2
• 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 108010068617 neonatal Fc receptor Proteins 0.000 description 2
• 238000002610 neuroimaging Methods 0.000 description 2
• 108010087904 neutravidin Proteins 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 238000007410 oral glucose tolerance test Methods 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 229920002451 polyvinyl alcohol Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 238000000751 protein extraction Methods 0.000 description 2
• 238000010791 quenching Methods 0.000 description 2
• 230000000171 quenching effect Effects 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000008521 reorganization Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
• 238000012502 risk assessment Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 229940103449 simcor Drugs 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 239000008362 succinate buffer Substances 0.000 description 2
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• 229940009349 vytorin Drugs 0.000 description 2
• PNAMDJVUJCJOIX-XVZWKFLSSA-N vytorin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-XVZWKFLSSA-N 0.000 description 2
• 229920003169 water-soluble polymer Polymers 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
• PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
• BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
• PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
• VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
• WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
• IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
• BIXCZKNSCJNZBL-LXGUWJNJSA-N (2r,3r,4s,5r)-2-(ethylamino)-3,4,5,6-tetrahydroxyhexanal Chemical compound CCN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO BIXCZKNSCJNZBL-LXGUWJNJSA-N 0.000 description 1
• MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
• OFUIFLZWMQEMFY-UHFFFAOYSA-N 1,2-dihydropyridazine-3,4-dione Chemical compound O=C1C=CNNC1=O OFUIFLZWMQEMFY-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
• VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• VUKYWZYFZZJLRZ-UHFFFAOYSA-N 2-[(1-amino-2-methyl-1-methyliminopropan-2-yl)diazenyl]-n',2-dimethylpropanimidamide;dihydrochloride Chemical compound Cl.Cl.CNC(=N)C(C)(C)N=NC(C)(C)C(=N)NC VUKYWZYFZZJLRZ-UHFFFAOYSA-N 0.000 description 1
• FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
• ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• KBDDIZRDKLGWGW-UHFFFAOYSA-N 3-[4-(3-aminopropylamino)butylamino]propylazanium;chloride Chemical compound [Cl-].NCCCNCCCCNCCC[NH3+] KBDDIZRDKLGWGW-UHFFFAOYSA-N 0.000 description 1
• ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 206010000599 Acromegaly Diseases 0.000 description 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 239000012099 Alexa Fluor family Substances 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 108090000363 Bacterial Luciferases Proteins 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• UEPVDULREMDSOL-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)O.C(=C)C1=C2C=CNC2=CC=C1.C1(CCC(N1)=O)=O Chemical compound C(C1=CC=CC=C1)(=O)O.C(=C)C1=C2C=CNC2=CC=C1.C1(CCC(N1)=O)=O UEPVDULREMDSOL-UHFFFAOYSA-N 0.000 description 1
• WYJFVKSIBDPXBT-UHFFFAOYSA-N C(CCCCCCC(=O)[O-])(=O)[O-].C(CCC)[NH2+]CCCC.C(CCC)[NH2+]CCCC Chemical compound C(CCCCCCC(=O)[O-])(=O)[O-].C(CCC)[NH2+]CCCC.C(CCC)[NH2+]CCCC WYJFVKSIBDPXBT-UHFFFAOYSA-N 0.000 description 1
• HZKPAMRPGHNDSC-UHFFFAOYSA-N C1CC(C(=N)CC1C=NN2C(=O)C=CC2=O)C(=O)O Chemical compound C1CC(C(=N)CC1C=NN2C(=O)C=CC2=O)C(=O)O HZKPAMRPGHNDSC-UHFFFAOYSA-N 0.000 description 1
• 101100168093 Caenorhabditis elegans cogc-2 gene Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 206010014486 Elevated triglycerides Diseases 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 206010073306 Exposure to radiation Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 108010015133 Galactose oxidase Proteins 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
• 102100022624 Glucoamylase Human genes 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 244000041633 Grewia tenax Species 0.000 description 1
• 235000005612 Grewia tenax Nutrition 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 102000019267 Hepatic lipases Human genes 0.000 description 1
• 108050006747 Hepatic lipases Proteins 0.000 description 1
• 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
• 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
• 108010003272 Hyaluronate lyase Proteins 0.000 description 1
• 102000001974 Hyaluronidases Human genes 0.000 description 1
• 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 238000012695 Interfacial polymerization Methods 0.000 description 1
• ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
• 241000221089 Jatropha Species 0.000 description 1
• 101710172072 Kexin Proteins 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 108091032995 L1Base Proteins 0.000 description 1
• 101150108666 LPG3 gene Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 101100135846 Macaca mulatta PCSK9 gene Proteins 0.000 description 1
• 239000004907 Macro-emulsion Substances 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
• 244000302512 Momordica charantia Species 0.000 description 1
• 235000009811 Momordica charantia Nutrition 0.000 description 1
• 240000002769 Morchella esculenta Species 0.000 description 1
• 235000002779 Morchella esculenta Nutrition 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100221487 Mus musculus Cog2 gene Proteins 0.000 description 1
• 231100000678 Mycotoxin Toxicity 0.000 description 1
• DDYWPQIFOIQIDN-UHFFFAOYSA-N N(=[N+]=[N-])C1=CC=C(C=NCCCCCCN=CC2=CC=C(C=C2)N=[N+]=[N-])C=C1 Chemical compound N(=[N+]=[N-])C1=CC=C(C=NCCCCCCN=CC2=CC=C(C=C2)N=[N+]=[N-])C=C1 DDYWPQIFOIQIDN-UHFFFAOYSA-N 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 229920002274 Nalgene Polymers 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 241000238413 Octopus Species 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 239000007977 PBT buffer Substances 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 241000609499 Palicourea Species 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
• WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000012343 Proprotein Convertase 9 Human genes 0.000 description 1
• 108010022249 Proprotein Convertase 9 Proteins 0.000 description 1
• 102000006437 Proprotein Convertases Human genes 0.000 description 1
• 108010044159 Proprotein Convertases Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 101100135853 Rattus norvegicus Pcsk9 gene Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 239000012506 Sephacryl® Substances 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 108090000787 Subtilisin Proteins 0.000 description 1
• 239000012505 Superdex™ Substances 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108010092464 Urate Oxidase Proteins 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
• 244000000188 Vaccinium ovalifolium Species 0.000 description 1
• 244000291414 Vaccinium oxycoccus Species 0.000 description 1
• 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 240000001866 Vernicia fordii Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 108010093894 Xanthine oxidase Proteins 0.000 description 1
• 102100033220 Xanthine oxidase Human genes 0.000 description 1
• 238000012452 Xenomouse strains Methods 0.000 description 1
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
• SZNQRASADHFMOO-UHFFFAOYSA-N [N+](=[N-])=C1CC=C(C=NCCN=CC2=CCC(C=C2)=[N+]=[N-])C=C1 Chemical compound [N+](=[N-])=C1CC=C(C=NCCN=CC2=CCC(C=C2)=[N+]=[N-])C=C1 SZNQRASADHFMOO-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 108010001818 alpha-sarcin Proteins 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229940027030 altoprev Drugs 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 238000002617 apheresis Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 description 1
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
• 229910052792 caesium Inorganic materials 0.000 description 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
• 229930195731 calicheamicin Natural products 0.000 description 1
• 125000001314 canonical amino-acid group Chemical group 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000002041 carbon nanotube Substances 0.000 description 1
• 229910021393 carbon nanotube Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 230000007870 cholestasis Effects 0.000 description 1
• 231100000359 cholestasis Toxicity 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000005354 coacervation Methods 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 235000020940 control diet Nutrition 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 235000004634 cranberry Nutrition 0.000 description 1
• 229940066901 crestor Drugs 0.000 description 1
• 238000002447 crystallographic data Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 229930191339 dianthin Natural products 0.000 description 1
• 108020001096 dihydrofolate reductase Proteins 0.000 description 1
• 125000005442 diisocyanate group Chemical group 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
• 229930188854 dolastatin Natural products 0.000 description 1
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
• 201000005577 familial hyperlipidemia Diseases 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 150000002222 fluorine compounds Chemical class 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 102000054767 gene variant Human genes 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• LYEKUMJVNIANHM-UHFFFAOYSA-N hexanedioic acid;hydrochloride Chemical compound Cl.OC(=O)CCCCC(O)=O LYEKUMJVNIANHM-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229940099552 hyaluronan Drugs 0.000 description 1
• KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960002773 hyaluronidase Drugs 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 229940044700 hylenex Drugs 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 239000002117 illicit drug Substances 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 239000003547 immunosorbent Substances 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
• 229940055742 indium-111 Drugs 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 208000021267 infertility disease Diseases 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000002198 insoluble material Substances 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 208000014384 isolated congenital growth hormone deficiency Diseases 0.000 description 1
• 201000002022 isolated growth hormone deficiency Diseases 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000012933 kinetic analysis Methods 0.000 description 1
• 229950005692 larotaxel Drugs 0.000 description 1
• SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
• 229940095570 lescol Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 229940002661 lipitor Drugs 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 229940092923 livalo Drugs 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000013627 low molecular weight specie Substances 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000012931 lyophilized formulation Substances 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 231100000682 maximum tolerated dose Toxicity 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Chemical class 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229940099246 mevacor Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 108010029942 microperoxidase Proteins 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 108010010621 modeccin Proteins 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 230000004001 molecular interaction Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 239000012452 mother liquor Substances 0.000 description 1
• 239000002636 mycotoxin Substances 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 150000002829 nitrogen Chemical class 0.000 description 1
• QJGQUHMNIGDVPM-OUBTZVSYSA-N nitrogen-15 Chemical compound [15N] QJGQUHMNIGDVPM-OUBTZVSYSA-N 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000001293 nucleolytic effect Effects 0.000 description 1
• 230000000474 nursing effect Effects 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 229940012843 omega-3 fatty acid Drugs 0.000 description 1
• 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
• 229950001094 ortataxel Drugs 0.000 description 1
• 230000010355 oscillation Effects 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 208000021255 pancreatic insulinoma Diseases 0.000 description 1
• 238000004091 panning Methods 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000012510 peptide mapping method Methods 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 235000020030 perry Nutrition 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 238000009521 phase II clinical trial Methods 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
• 208000003068 pituitary dwarfism Diseases 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
• 108010054442 polyalanine Proteins 0.000 description 1
• 230000003234 polygenic effect Effects 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 229940089484 pravachol Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 231100000654 protein toxin Toxicity 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 229920005604 random copolymer Polymers 0.000 description 1
• 229910052761 rare earth metal Inorganic materials 0.000 description 1
• 150000002910 rare earth metals Chemical class 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 229940026314 red yeast rice Drugs 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
• 238000007873 sieving Methods 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000011146 sterile filtration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
• 229950009016 tesetaxel Drugs 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 239000003451 thiazide diuretic agent Substances 0.000 description 1
• CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
• RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
• 229930013292 trichothecene Natural products 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 231100000402 unacceptable toxicity Toxicity 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
• 229940072168 zocor Drugs 0.000 description 1